Status: Recruiting
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Participants needed: 105
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Rgenta Therapeutics IncUpdated: Nov 14, 2025Locations: 10
Eligibility criteria
Histologically confirmed ACC or CRC [+5]
Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Da... [+17]